News Covered by Medical Dialogue: Journal Club- Guideline led COPD Management: Vilanterol or formoterol?

Dr. Garima Soni discusses highlights from a recent review featured in the Annals of the National Academy of Medical Sciences and published by Scientific Scholar. The article examines the evolving role of vilanterol, a long-acting β2-agonist, in comparison with formoterol, based on current GINA 2024 and GOLD 2024 guidelines. With a focus on efficacy, safety, and patient-centered outcomes, the review supports tailored treatment approaches for asthma and COPD, noting vilanterol’s potential benefits in adherence, quality of life, and clinical outcomes—particularly in the context of COPD.

This news was covered by Medical Dialogues.